These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15988505)

  • 1. Cancer biology: summing up cancer stem cells.
    Huntly BJ; Gilliland DG
    Nature; 2005 Jun; 435(7046):1169-70. PubMed ID: 15988505
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamics of chronic myeloid leukaemia.
    Michor F; Hughes TP; Iwasa Y; Branford S; Shah NP; Sawyers CL; Nowak MA
    Nature; 2005 Jun; 435(7046):1267-70. PubMed ID: 15988530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roots of clinical resistance to STI-571 cancer therapy.
    Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
    [No Abstract]   [Full Text] [Related]  

  • 5. Mathematical models of cancer stem cells.
    Michor F
    J Clin Oncol; 2008 Jun; 26(17):2854-61. PubMed ID: 18539964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted cancer treatment: resisting arrest.
    Wodarz D
    Nat Med; 2006 Oct; 12(10):1125-6. PubMed ID: 17024205
    [No Abstract]   [Full Text] [Related]  

  • 8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 10. [STI571: the resistance organizes!].
    Jeanteur P
    Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage.
    Jacquel A; Herrant M; Legros L; Belhacene N; Luciano F; Pages G; Hofman P; Auberger P
    FASEB J; 2003 Nov; 17(14):2160-2. PubMed ID: 14597677
    [No Abstract]   [Full Text] [Related]  

  • 14. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
    López-Karpovitch X
    Rev Invest Clin; 2003; 55(2):191-5. PubMed ID: 12827926
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
    Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
    Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance and relapse with imatinib in CML: causes and consequences.
    Deininger M
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counterpoint: Data first.
    Golub T
    Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.